28.7%
Weight Loss
Phase 3, 68 weeks
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Triple-Action Weight Loss Compound
GLP-3 (RT)
LY3437943GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.
Dosage
Quantity
1
From
$79.99
4 interest-free payments of $20.00We accept
GLP-3 (RT)$79.99
Free shippingon orders over $150
30-day money-backguarantee
Secure checkout256-bit SSL
3
Receptor Targets
GIP + GLP-1 + Glucagon
1x
Weekly Injection
Subcutaneous
86%
Liver Fat Reduced
Phase 2, 48 weeks
5.8k
People Studied
Across all trials
What Makes Retatrutide Different?
The Science, Simplified
Three Receptors, One Molecule
Unlike Ozempic (which targets 1 receptor) or Mounjaro (which targets 2), Retatrutide activates three different hormone receptors at once. Each receptor triggers a different metabolic pathway — and together, they deliver more powerful effects than any single-target approach.
GIPStrongest
GIP Receptor
Glucose-dependent Insulinotropic Polypeptide
Helps release insulin
Improves fat metabolism
Enhances satiety
GLP-1Moderate
GLP-1 Receptor
Glucagon-like Peptide-1
Reduces appetite
Slows digestion
Improves blood sugar
GCGTargeted
Glucagon Receptor
The "Secret Weapon"
Burns liver fat directly
Increases energy burn
Lowers cholesterol
Why Glucagon Matters
The Third Receptor Advantage
The glucagon receptor is what sets retatrutide apart. In trials, researchers observed that activating this receptor:
Directly burns fat stored in the liver — which may explain why trial participants saw up to 86% reduction in liver fat.
Ozempic / WegovyGLP-1 only
Mounjaro / ZepboundGLP-1 + GIP
RetatrutideGLP-1 + GIP + GCG
What Researchers Observed
Latest clinical trial data
71lbs
Average Weight Lost at Highest Dose
Weight Loss by Dose Level
12mg dose-28.7%
9mg dose-26.4%
Placebo-2.1%
Trial details: 445 adults • 68 weeks • Starting weight ~248 lbs • Results announced December 2025
Weight Loss Milestones
Percentage of Participants Who Reached Each Goal
At the highest dose (12mg), here's how many participants achieved meaningful weight loss:
100%of participants
Lost 5%+at 12mg dose
58.6%of participants
Lost 25%+at 12mg dose
39.4%of participants
Lost 30%+at 12mg dose
For context: Losing 5% of body weight is considered 'clinically meaningful.' Nearly 4 in 10 participants lost 30% or more — results previously only seen with bariatric surgery.
How It Compares
Weight Loss: Retatrutide vs. Other Options
Retatrutide
28.7%Triple
Tirzepatide
22.5%Dual
Semaglutide
17%Single
Note: These numbers are from different clinical trials with different participant groups. No head-to-head studies have been conducted yet.
Results by Dose Level
Researchers observed a clear dose-dependent response — higher doses produced more weight loss.
12mg weekly
-24.2%8mg weekly
-22.8%4mg weekly
-17.5%1mg weekly
-8.7%Beyond Weight Loss
Other benefits observed in trials
-86%
Liver FatFat stored in liver cells. Less than 5% is considered normal. Above 5% is 'fatty liver disease.'
93% reached normal liver fat levels
Nature Medicine-2.2%
HbA1cA measure of average blood sugar over 2-3 months. Normal is under 5.7%, diabetes is 6.5%+
82% of diabetic participants reached healthy levels
The Lancet72%
Prediabetes Reversed
Participants returned to normal blood sugar levels
NEJM-38%
TriglyceridesA type of fat in your blood. High levels increase heart disease risk.
Significant reduction in blood fat levels
Meta-AnalysisBody Composition
What Kind of Weight Was Lost?
Like all GLP-1 medications, participants lost some lean mass along with fat. The ratio was similar to other weight loss drugs.
Fat mass lost
+75%Lean mass lost
+25%Tip: Researchers recommend resistance training during treatment to help preserve muscle mass.
Heart Health
Cardiovascular Risk Markers
Multiple markers of heart health improved during trials.
TriglyceridesA type of fat in your blood↓ 38%
LDL Cholesterol"Bad" cholesterol that builds up in arteries↓ 18%
HDL Cholesterol"Good" cholesterol that helps remove bad cholesterol↑ 12%
Systolic Blood Pressure↓ 7 mmHg
Joint Health
Knee Osteoarthritis Pain
75.8%
improvement in pain scores at 12mg dose
Notable: 12% of participants became completely pain-free after 68 weeks vs only 4% on placebo.
What Researchers Learned About Dosing
From clinical trial protocols
In the TRIUMPH trials, researchers started participants at a low dose and gradually increased it over several weeks. This approach helped reduce side effects.
Clinical Trial Protocol
TRIUMPH Trial Protocol
Standard escalation protocol used in Phase 2 and Phase 3 trials. Gradual increase helps the body adjust and minimizes side effects.
1-4Week
2mg
Once weekly
Starting dose — all participants started here
5-8Week
4mg
Once weekly
First increase — dose doubled after 4 weeks
9-12Week
6mg
Once weekly
Continued gradual escalation
13+Week
9mg or 12mg
Once weekly
Target maintenance dose for remainder of trial
Weekly subcutaneous injection
In Phase 2, participants who started at higher doses (4mg) had significantly more nausea than those who started at 2mg
Gradual titration helps the body adjust
Pharmacokinetics
How It Works in the Body
Half-lifeHow long until half the dose is eliminated from your body~6 days
Peak concentrationWhen blood levels of the compound are highest24-48 hours
Steady stateWhen blood levels stabilize with regular dosing~4 weeks
BioavailabilityHow much of the injected dose reaches the bloodstream~65%
AdministrationSubcutaneous injection
Injection frequencyOnce weekly
Once-weekly dosing maintains stable blood levels due to 6-day half-life.
No tolerance observed — participants continued losing weight throughout 48-68 week studies without needing dose increases.
Side Effects Observed in Trials
What researchers reported
Like other GLP-1 medications, the most common side effects were gastrointestinal in nature. Most were mild to moderate and occurred mainly during the dose escalation period, then improved.
Common Digestive Issues
43%
Nausea
mild
33%
Diarrhea
mild
25%
Constipation
mild
21%
Vomiting
moderate
Unique to Retatrutide
DysesthesiaUnusual skin sensations like tingling, burning, or numbness
Retatrutide 12mg20.9%
30xhigher
Placebo0.7%
This side effect is unique to Retatrutide and is not commonly seen with other GLP-1 medications. It's likely related to the glucagon receptor activity.
- Described as tingling, burning, or numbness sensations
- Usually mild and temporary
- 20.9% at 12mg vs 0.7% on placebo
- May be caused by glucagon receptor's effect on nerves
Discontinuation Rates
How Many Stopped Due to Side Effects
12mg18.2%
9mg12.2%
4mg6.8%
Placebo4.0%
Some participants stopped because of 'perceived excessive weight loss' — they lost more than they wanted.
Trial Exclusions
Who Couldn't Participate in Trials
History of pancreatitisThyroid cancer or MEN2 syndromeSevere kidney or liver diseaseType 1 diabetesHistory of eating disordersPregnant or breastfeeding
Rare but Serious Events
Gallstones: <5% (similar to other GLP-1 medications)
Pancreatitis: <1% (careful monitoring recommended)
Injection site reactions: <3%
Researcher Notes
- These rates are at the 12mg dose — lower doses had fewer side effects.
- Most GI side effects improve after the first 4-8 weeks as the body adjusts.
Compound Information
Technical specifications
Molecular Profile
What Is Retatrutide?
TypeSynthetic peptide
CAS Number2381089-83-2
Molecular Weight4,731 g/mol
Amino Acids39
Fatty Acid ChainA fatty acid attached to extend how long it stays active in your bodyC20 diacid
Storage Requirements
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
-20°C•24+ months
Reconstituted
2-8°C•~30 days
Development Status
Where It Stands
Phase 3 ActiveNot FDA Approved
DeveloperEli Lilly
Trial ProgramTRIUMPH
Phase 3 ResultsExpected 2026
Potential Approval~2027
Frequently Asked Questions
Common questions about Retatrutide research
Retatrutide is a triple-action agonist that targets three receptors (GIP, GLP-1, and Glucagon), while Ozempic targets only GLP-1 and Mounjaro targets GLP-1 and GIP. The addition of the glucagon receptor may explain the enhanced weight loss (28.7% vs 17% for semaglutide, 22.5% for tirzepatide) and the remarkable 86% liver fat reduction observed in trials.
Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program). Based on the trial timeline, Phase 3 results are expected in 2026, with potential FDA approval around 2027. This timeline is speculative and subject to change based on regulatory processes.
No tolerance was observed in trials. Participants continued losing weight throughout 48-68 week studies without needing dose increases. Weight loss curves showed continued progress, not plateaus from desensitization. Weight tends to slow after ~24 weeks but this reflects reaching a new equilibrium, not drug tolerance.
Like other GLP-1 medications, weight regain is expected if treatment is discontinued. The TRIUMPH program is testing a 4mg maintenance dose for long-term use. The longest data available is 68 weeks (Phase 3) and 48 weeks (Phase 2).
Gastrointestinal side effects were most common: nausea (43%), diarrhea (33%), constipation (25%), and vomiting (21%) at the 12mg dose. These typically decreased over time. Unique to Retatrutide is dysesthesia (unusual skin sensations) in about 21% at the highest dose — this is likely related to glucagon receptor activity and was generally mild.
Lyophilized (powder): -20°C for 24+ months. Reconstituted: 2-8°C for ~30 days. Avoid freeze/thaw cycles and protect from light. Keep refrigerated after reconstitution.
Sources & References
Peer-reviewed research
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
